To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Summary

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 23 January 2025

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 23 January 2025

   Introduced

   Introduced in House

   Source: IntroReferral

3. 23 January 2025

   Introduced

   Introduced in House

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

2 official files

• Introduced in House

  Introduced in House · EN · 23 January 2025

  DownloadOpen at official source

• Introduced in House

  summary · EN · 23 January 2025

  Open at official source

Sponsors

• Diana Harshbarger · R · Sponsor
• Rep. Hern, Kevin [R-OK-1] · R · Sponsor
• Rep. Bost, Mike [R-IL-12] · R · Sponsor
• Rep. Miller, Mary E. [R-IL-15] · R · Sponsor
• Rep. Weber, Randy K. Sr. [R-TX-14] · R · Sponsor
• Rep. Babin, Brian [R-TX-36] · R · Sponsor
• John Moolenaar · R · Sponsor
• Rep. Webster, Daniel [R-FL-11] · R · Sponsor
• James Baird · R · Sponsor
• Rep. Higgins, Clay [R-LA-3] · R · Sponsor
• Rep. Feenstra, Randy [R-IA-4] · R · Sponsor
• Rep. Yakym, Rudy [R-IN-2] · R · Sponsor
• Rep. Biggs, Andy [R-AZ-5] · R · Sponsor
• Gary Palmer · R · Sponsor
• Rep. Guest, Michael [R-MS-3] · R · Sponsor
• Andy Harris · R · Cosponsor
• Rep. Self, Keith [R-TX-3] · R · Cosponsor
• Rep. Biggs, Sheri [R-SC-3] · R · Cosponsor
• Rep. Messmer, Mark [R-IN-8] · R · Cosponsor
• · hsif00 · Standing

Related records

No cross-record relationships stored yet.